The Manufacturers Life Insurance Company Invests $142,000 in Celcuity Inc. (NASDAQ:CELC)

The Manufacturers Life Insurance Company acquired a new position in Celcuity Inc. (NASDAQ:CELC) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,826 shares of the company’s stock, valued at approximately $142,000.

A number of other large investors have also added to or reduced their stakes in CELC. Bleakley Financial Group LLC bought a new position in shares of Celcuity during the fourth quarter valued at about $146,000. Vanguard Group Inc. boosted its position in Celcuity by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company’s stock valued at $21,624,000 after acquiring an additional 24,429 shares in the last quarter. Corebridge Financial Inc. boosted its position in Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company’s stock valued at $213,000 after acquiring an additional 1,858 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Celcuity by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company’s stock valued at $3,112,000 after purchasing an additional 16,035 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Celcuity by 21.6% during the fourth quarter. Wellington Management Group LLP now owns 62,776 shares of the company’s stock valued at $822,000 after purchasing an additional 11,165 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CELC. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Celcuity in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $30.80.

Celcuity Trading Up 0.9%

Shares of Celcuity stock opened at $10.61 on Monday. The company has a market capitalization of $401.47 million, a P/E ratio of -4.07 and a beta of 0.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The company has a fifty day moving average of $10.15 and a 200 day moving average of $11.64. Celcuity Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $19.77.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. On average, sell-side analysts anticipate that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.